Dalrada Financial Corporation (OTCMKTS: DFCO) has continued to move higher in recent trading since reversing off $0.0655 lows in December. The stock has been on the move since the Company reported its Dalrada Health division has been experienced strong revenue growth of $13.6 million, representing a 683% year-over-year increase. The Company’s CEO Mr. Brian Bonar took advantage of recent prices purchasing 141,360 shares at $0.10 bringing his personal share ownership to 5,758,513 shares.  

DFCO also got a recent boost after the Company announced a new operating structure in response to accelerated company growth and a renewal to its corporate vision. At the heart of this new operating model is a change of the company’s health division name from Dalrada Health to Genefic. Additional changes will include a new board structure, an appointment of a Chief Executive Officer and Chief Operating Officer (both of which are expected to be made from the existing management pool), a new operating location, and a new website. All of these changes are specifically designed to support the new company in its mission, goals, and services.

Dalrada Financial Corporation (OTCMKTS: DFCO) continues to grow its footprint to include the unique business divisions: Dalrada Health, Dalrada Energy Services, Dalrada Precision Manufacturing, and Dalrada Technologies. Within each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us. 

Dalrada Health delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, When the world needs advanced health care, Dalrada Health delivers with ingenuity, accessibility, and affordability. This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level. 

DFCO continues to report rapid growth in revenues reporting $4.3 million in revenues during Q1, 2023. The Company’s CEO Brian Bonar said: “I am pleased to report positive financial growth during Q1 of 2023, reflecting successful entries into carefully-selected market sectors. As we look ahead to the rest of 2023, we will maintain our focus on both stabilized and accelerated revenue growth to further enhance shareholder value. Advanced technologies like Web 3.0-based digital twin and metaverse enablement are providing multiple partnership opportunities, particularly within the federal government. As a result, Dalrada is poised to capture additional momentum in specific business markets, including green energy, as Fiscal 2023 continues.” 

In the 2022 fiscal year, Dalrada Health experienced strong revenue growth of $13.6 million, representing a 683% year-over-year increase. This growth reflects the demonstrated demand within today’s health environment for core, frontline health products and services – including robust virus and disease-screening capabilities, pharmaceutical goods, and holistic wellness clinics. 

$DFCO NEWS: Dalrada announces new Board of Directors for new health care division, Genefic, formerly known as Dalrada Health. The Genefic board will be comprised of six leaders who bring diverse perspectives and acute business experience. Read more: https://t.co/WqpGSh40a0 pic.twitter.com/YUF3S2RTyL

— Dalrada Financial Corporation™ (@Dalrada_DFCO) January 25, 2023

To Find out the inside Scoop on DFCO Subscribe to investmillion.com Right Now by entering your Email in the box below

DFCO continues to grow via acquisition acquiring Bothof Brothers Construction, a leader in high-end construction, on October 7, 2022. The acquisition adds significant value to Dalrada’s fast-growing Energy Services division by providing more energy-efficient building capabilities. Founded in 1995, Bothof Brothers Construction has built its business on a meticulous dedication to quality, completing projects that span residential home builds, government housing developments, complex commercial builds, and high-end custom homes. 

Back in December the Company reported Dalrada Health’s Empower Genomics vaccine program received approval by the Centers for Disease Control and Prevention (CDC). Driven by Empower Genomics team member, Julia Zavala, this accomplishment puts the Dalrada Health subsidiary on equal footing with large pharmacies and drug store chains in regard to the distribution and administration of vaccines to at-risk populations within the greater San Diego area. Empower Genomics now delivers Influenza (Flu) and COVID-19 vaccines to long term care facilities, infants and toddlers, and the general public through community sites and mobile clinics. 

On January 17 the Company appointed Harvey Hershkowitz as Chairman and Chief Executive Officer of Genefic (formerly Dalrada Health). Mr. Hershkowitz has served as a board member of Dalrada Financial Corporation since July 2020, where his extensive track record in business and the health care industry has furthered Dalrada’s global vision and business expansion strategy. Genefic will focus on improving health outcomes for people around the world through reimagined patient care, and Brian Bonar, Dalrada’s Founder and Chief Executive Officer, affirms that Hershkowitz is the ideal candidate for the position. 

 We have something big coming Subscribe Right Now!

DFCO) has continued to move higher in recent trading since reversing off $0.0655 lows in December. The stock has been on the move since the Company reported its Dalrada Health division has been experienced strong revenue growth of $13.6 million, representing a 683% year-over-year increase. This growth reflects the demonstrated demand within today’s health environment for core, frontline health products and services – including robust virus and disease-screening capabilities, pharmaceutical goods, and holistic wellness clinics. DRCR also got a boost after the Company announced a new operating structure in response to accelerated company growth and a renewal to its corporate vision. At the heart of this new operating model is a change of the company’s health division name from Dalrada Health to Genefic. Additional changes will include a new board structure, an appointment of a Chief Executive Officer and Chief Operating Officer (both of which are expected to be made from the existing management pool), a new operating location, and a new website. All of these changes are specifically designed to support the new company in its mission, goals, and services. We will be updating on DFCO when more details emerge so make sure you are subscribed to investmillion.com by entering your email below.

Disclosure: we hold no position in DFCO either long or short and we have not been compensated for this article.